MicroPort CardioFlow Medtech Crecimiento futuro
Future controles de criterios 5/6
MicroPort CardioFlow Medtech is forecast to grow earnings and revenue by 102.9% and 23.5% per annum respectively. EPS is expected to grow by 103% per annum. Return on equity is forecast to be 1.4% in 3 years.
Información clave
102.9%
Tasa de crecimiento de los beneficios
103.0%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 17.4% |
| Tasa de crecimiento de los ingresos | 23.5% |
| Rentabilidad financiera futura | 1.4% |
| Cobertura de analistas | Low |
| Última actualización | 01 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 753 | 99 | 8 | 23 | 3 |
| 12/31/2025 | 571 | -39 | -99 | -94 | 3 |
| 12/31/2024 | 454 | -162 | -70 | -45 | 2 |
| 6/30/2024 | 383 | -349 | -182 | -167 | N/A |
| 3/31/2024 | 360 | -410 | -210 | -187 | N/A |
| 12/31/2023 | 336 | -472 | -237 | -207 | N/A |
| 9/30/2023 | 319 | -491 | -250 | -216 | N/A |
| 6/30/2023 | 303 | -511 | -263 | -226 | N/A |
| 3/31/2023 | 277 | -483 | -247 | -204 | N/A |
| 12/31/2022 | 251 | -454 | -232 | -183 | N/A |
| 9/30/2022 | 245 | -345 | -270 | -191 | N/A |
| 6/30/2022 | 239 | -236 | -309 | -199 | N/A |
| 3/31/2022 | 220 | -209 | -290 | -180 | N/A |
| 12/31/2021 | 201 | -183 | -270 | -162 | N/A |
| 9/30/2021 | 176 | -265 | N/A | N/A | N/A |
| 6/30/2021 | 151 | -346 | N/A | N/A | N/A |
| 3/31/2021 | 128 | -372 | N/A | N/A | N/A |
| 12/31/2020 | 104 | -398 | -168 | -110 | N/A |
| 12/31/2019 | 22 | -145 | -191 | -143 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: MROP.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Beneficios vs. Mercado: MROP.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: MROP.F is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: MROP.F's revenue (23.5% per year) is forecast to grow faster than the US market (8.9% per year).
Ingresos de alto crecimiento: MROP.F's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: MROP.F's Return on Equity is forecast to be low in 3 years time (1.4%).